{
  "extraction_metadata": {
    "timestamp": "2025-09-04T14:57:11.000710",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 6,
    "total_picos": 10
  },
  "picos_by_country": {
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic treatment with anticancer drugs (targeted therapy, immunotherapy and cytostatics)",
          "Outcomes": "symptom control, preservation of quality of life, prolonged survival"
        },
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "palliative radiotherapy",
          "Outcomes": "symptom control, preservation of quality of life, prolonged survival"
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1539
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel or docetaxel plus nintedanib",
          "Outcomes": "overall survival, progression-free survival, health-related quality of life, objective response rate, time before cancer worsens, potential cost-effectiveness"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5915
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": "stronger consensus, approved targeted therapy"
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 692
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "increased progression free survival, increased quality of life, little to no difference in overall survival, little to no difference in objective response rate, little to no difference in adverse events"
        },
        {
          "Population": "patients with non–smallcell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": "increased progression free survival, increased quality of life, little to no difference in overall survival, little to no difference in objective response rate, little to no difference in adverse events"
        }
      ],
      "ChunksUsed": 9,
      "ContextTokens": 1934
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib as part of a Compassionate Access Authorization (ACA)",
          "Outcomes": "potential risk of serious side effects on the skin"
        },
        {
          "Population": "advanced or metastatic non-small cell bronchial cancer: in the presence of a KRAS p.G12C mutation, having escaped a second line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib as part of a Compassionate Access Authorization (ACA)",
          "Outcomes": "potential risk of serious side effects on the skin"
        }
      ],
      "ChunksUsed": 14,
      "ContextTokens": 3363
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib or docetaxel",
          "Outcomes": "response rates, adverse events"
        },
        {
          "Population": "patients with active KRAS G12C and 0-2 performance status",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "2nd line treatment with sotorasib or adagrasib",
          "Outcomes": "response rates, adverse events"
        }
      ],
      "ChunksUsed": 16,
      "ContextTokens": 3464
    }
  }
}